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Abstract: Psychiatric patients often suffer from stress, anxiety and depression. Various plant extracts are known to
fight stress (valerian), anxiety (passion flower) or depression (St. John’s wort). NEURAPAS
® balance is a mixture of
these three extracts and has been designed to cover this complex of psychiatric conditions. The study was initiated
to quantitatively assess the effect of this combination on brain electric activity.
Method: Quantitative electroencephalogram (EEG) current source density (CSD) recording from 16 healthy male
and female human volunteers (average age 49 years) was used in a randomized, placebo-controlled cross over
study. Recordings were performed 0. 5, 1. 5, 3 and 4 hours after administration of the preparations under the
conditions of 6 min eyes open and 5 min d2 concentration test, mathematical calculation test and memory test,
respectively. All variables (electric power within 6 frequency ranges at 17 electrode positions) were fed into a linear
discriminant analysis (eyes open condition). In the presence of mental load these variables were used to construct
brain maps of frequency changes.
Results: Under the condition of mental load, centro-parietal spectral power remained statistically significantly lower
within alpha1, alpha2 and beta1 frequencies in the presence of verum in comparison to placebo. Discriminant
analysis revealed a difference to placebo 3 and 4 hours after intake of 6 tablets of NEURAPAS
® balance. Data
location within the polydimensional space was projected into the area of the effects of sedative and anti-
depressive reference drugs tested earlier under identical conditions. Results appeared closer to the effects of
fluoxetine than to St. John’s wort.
Conclusions: Analysis of the neurophysiological changes following the intake of NEURAPAS
® balance revealed a
similarity of frequency changes to those of calming and anti-depressive drugs on the EEG without impairment of
cognition.
Trial registration: ClinicalTrials.gov: NCT01047605
Background
People today face quite a number of psychic challenges.
Working life produces numerous stress situations, which
sometimes are difficult to cope with. Permanent pres-
sure of this kind in many cases leads to adaptive
mechanisms of the brain and successful coping. But
there are also numerous cases where these protective
mechanisms do not work or show exhaustion with time.
Very often anxiety and depression are the result of such
continuous environmental exposures. Under theses cir-
cumstances patients need help. Broad use of synthetic
drugs like benzodiazepines or serotonin reuptake
inhibitors is for example accompanied by serious side
effects like cognitive impairment in the case of benzo-
diazepines [1] or heart and circulation problems in the
case of reuptake inhibitors [2]. An alternative solution
can be provided by administration of natural remedies.
For centuries the calming effect of passion flower and
valerian root extract have been recognized and were
partially confirmed in recent clinical studies. For exam-
ple preoperative oral Passiflora incarnate reduces anxiety
in ambulatory surgery patients [3] and there is tentative
evidence that extract of Valeriana wallichii attenuated
stress and anxiety [4]. Efficacy and tolerability of Hyperi-
cum extract (St. John’s wort) for the treatment of mild
to moderate depression has been documented [5]. This
knowledge has resulted in numerous formulations of
dietary supplements and herbal extracts for relaxation
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any medium, provided the original work is properly cited.and anxiolytic action (for review s. [6]. Nearly, all clini-
cal studies dealing with the treatment of depression by
St. John’s wort have provided solid evidence for its effi-
cacy during treatment. But with respect to anxiety there
is a lack of rigorous studies in this area [7].
In order to cover a broader range of possible psychia-
tric distortions a film-coated tablet with a mixture of
extracts of valerian root, passion flower herb and St.
John’s wort herb has been developed for pharmacologi-
cal treatment of these conditions under the name of
NEURAPAS
® balance. This combination of extracts has
been characterized pharmacologically in vitro and in
vivo [8]. It was shown for the first time that Passiflora
significantly enhances the potency of Hypericum (St.
John’s wort) in two preclinical models: serotonin reup-
take and forced swimming test.
With the availability of new encephalographic techni-
ques like continuous online current source density mea-
surements (CATEEM
®) the quantitative description of
brain function has entered a stage where the measure-
ment of even very subtle changes of physiological brain
activity has become feasible [9]. The aim of the present
clinical study was to substantiate the effectiveness of
this preparation by current source density (CSD) analy-
sis of brain activity in the presence of various mental
challenges. This technology-as a special form of quanti-
tative pharmaco-EEG-has been used widely in the past
for the characterization of drug effects.
Methods
Subjects
Sixteen healthy volunteers (8 males, 48,7 ± 7 years old
and 8 females, 47 ± 8 years old) were recruited by
advertisement and participated in this study. They
underwent a medical examination before entering the
trial. Subjects reporting neurological disturbances of the
central nervous system (using DSM-III criteria) were
excluded from the study. Subjects with a history of drug
or ethanol abuse or participation in another study
within the last six months were also excluded. It was
ensured that they were not on alcohol. On the day of
examination no beverages containing caffeine were
allowed within the last 12 hours preceding the EEG
recording. The study was carried out according to the
declaration of Helsinki [10] on human rights and was
approved by the local ethics committee of the State
Medical Association Hessen (Frankfurt, Germany) and
government authorities (BfArM, Bonn, Germany). All
subjects were informed about the goals of the study in
detail and gave their written informed consent to parti-
cipate. Each subject was randomly allocated to either
the functionally active preparation or placebo within a
crossover design.
EEG Recording
Subjects sat alone in a quiet separate room in a comfor-
table easy chair. The light was dimmed. Baseline record-
ing of 6 min under the condition of eyes open was
followed by performance of three cognitive tests: a con-
centration test (d2-test) [11], a mathematical calculation
test (according to [12]) and a memory test consisting in
the presentation of a row of letters and numbers, which
appeared for 4 s on a screen followed by 10 s black
screen. After this a multiple choice of four possible
answers was presented.
All recordings were repeated 0. 5 h, 1. 5 h, 3 and 4 h
after the administration of the tablets (overview in Fig-
ure 1). Between the measurement sessions the subjects
spent their time in the facility’s break room. All experi-
ments took place at the same time of the day (starting
at 8 h a. m.).
The EEG was recorded bipolarly from 17 surface elec-
trodes according to the international 10/20 system with
Cz as physical reference electrode for calculation of the
common average reference (Computer aided topographi-
cal electroencephalometry: CATEEM
® -f r o mM e w i c o n
GmbH, 4164 Schwarzenberg, Austria) using an electro-
cap [13]. The raw signals were amplified, digitalized
(2048 Hz/12 bit) and transmitted via fiber optical
devices to the computer. The automatic artefact rejec-
tion of the CATEEM
®-System, which eradicates EEG-
alterations caused by eye blinks, swallows, respiration
etc. during the recording was visually controlled and
individually adjusted by the investigator. Electrocardio-
gram (ECG) and electrooculogram (EOG) were recorded
in one channel each in order to facilitate detection of
those signals superposed on to the EEG. The artefact
rejection set-up was observed for about 5 minutes prior
to the start of the recording to ensure, that all artefacts
were correctly recognized and eliminated from further
evaluation. For safety purposes the original raw data
were saved on optical disk in order to allow re-evalua-
tion of the artefact rejection mode if necessary. In these
cases the experimental session was re-examined off-line
Figure 1 Time line of EEG recording. Time line of EEG recording
before and after administration of the preparations.
Dimpfel et al. BMC Psychiatry 2011, 11:123
http://www.biomedcentral.com/1471-244X/11/123
Page 2 of 15with a newly adapted rejection mode. The amount of
rejected data was determined automatically and given in
percent of total recording time. Nevertheless the entire
recording and the computer-based automatic artefact
rejection were continuously supervised and adjusted by
a trained technician [14]. Logarithm of CSD data was
taken for discriminant analysis in order to approach
normal distribution of values, which underwent fre-
quency analysis for quantitative evaluation as proposed
for the first time nearly 80 years ago [15].
In this study the EEG was computed not in the poten-
tial mode measured as voltage, but in a surface charge
mode obtained by Laplacian estimates also known as
current source density (CSD) analysis [16]. The charge
is the 2
nd derivative of the potential and gives the spatial
curvature of the potential. All calculations are based on
the standard set-up of the 10/20 system of recording.
Under the condition of using a homogenous, steadily
conducting medium the surface charge mode provides
the source density of the electrical flow on the cortex
surface. Whereas the EEG in the potential mode tends
t op r o d u c eam o r ee x t e n s i v ea n dd i f f u s ep i c t u r eo f
changes, the Laplacian estimate acts as a spatial filter
emphasizing local sources over distant sources. Others
[16] were able to demonstrate, that spectral parameters
obtained from the CSD showed higher correlations with
computer tomography measures than those calculated
from the potential mode of the EEG. We therefore used
this methodology in order to describe the focal changes
of brain activity. Using a Lagrange interpolation, signals
from 82 additional virtual electrodes were calculated to
provide high-resolution topographical maps. The signals
of all 99 electrode positions (17 real and 82 virtual)
underwent the Fast Fourier Transformation (FFT) based
on 4-second sweeps of data epochs (Hanning window).
Data were analysed from 0. 86 to 35 Hz using the
CATEEM
® software. In this software the resulting fre-
quency spectra are divided into six frequency bands:
delta (1. 25-4. 50 Hz), theta (4. 75-6. 75 Hz), alpha1 (7.
00-9. 50 Hz), alpha2 (9. 75-12. 50 Hz), beta1 (12. 75-18.
50 Hz) and beta2 (18. 75-35. 00 Hz). This frequency
analysis is based on absolute spectral power values. Col-
our coding of the maps is achieved by transforming the
content of the power spectrum into the so-called colour
vision mode pictures (i. e. frequencies are converted
into spectral colours with a resolution of 0. 25 Hz,
which gives 140 colours which are then mixed according
to spectral content to give one map similar to the RGB
mode of TV pictures). Data acquisition and analysis
were carried out simultaneously and provide topographi-
cal maps displayed on-line on the computer screen. The
maps show the relative, time-averaged, functional
changes of electric brain activity of each specific record-
ing condition in comparison to the reference period at
the beginning of each recording session during the
relaxed state with open eyes.
Band powers are firstly compared between placebo
and verum during relaxation, then the effects of differ-
ent mental loads are determined in the absence of either
placebo or verum, and finally the results of verum and
placebo are compared under different mental loads.
Statistics
EEG data from the first recording session before drug
intake are given as absolute numbers (μV
2). By setting
the absolute electric power of this first pre-drug record-
ing to 100%, changes produced by the preparations are
given as percentage from this pre-drug condition.
Except for the construction of brain maps only those
particular electrode positions were used for the numeric
comparison of verum to placebo during mental load,
which have been found to change during the particular
mental challenge. For explorative statistical evaluation
the nonparametric sign test was used. For mathematical
classification of drug effects the linear discriminant ana-
lysis according to Fischer was used. Results from the
first three discriminant functions were projected into
s p a c e( x ,ya n dzc o o r d i n a t e s ) ,w h e r e a sr e s u l t sf r o mt h e
fourth to sixth discriminant functions were coded into
red, green and blue, respectively, followed by an additive
colour mixture (so-called RGB-mode). Reference pre-
parations used for comparison have been tested in our
lab earlier under identical conditions. These data were
processed by linear discriminant analysis. Thereafter we
used the same transformation by using this projection
without any further discriminant analysis procedure for
depiction of Neurapas
® balance.
Psychometric performance was evaluated by the math-
ematical product of “quantity × quality”, where quantity
was defined as the number of correct answers and qual-
ity as the number of correct answers divided by the
number of tasks tackled.
Preparation
NEURAPAS
® balance is a film-coated tablet containing
a combination of special dried extracts: 60 mg “St John’s
wort Herb” (4. 6-6. 5:1), extractant: ethanol 38% (m/m),
28 mg “Valerian root” (3. 8-5. 6:1), extractant: ethanol
40% (m/m), and 32 mg “passion flower herb” (6. 25-7.
1:1), extractant: ethanol 60% (m/m). NEURAPAS
® bal-
ance is registered in different European countries for the
treatment of mild depression, low mood, anxiety, and
sleep disorders and marketed by Pascoe Pharmazeu-
tische Präparate GmbH, Giessen, Germany. The verum
preparation consisted of the maximum daily dosage of 6
tablets of NEURAPAS
® balance. At least one week
passed between administrations within the crossover
design.
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Analysis of Single Frequency Ranges during Relaxation
Source density analysis of the primary recording of the
reference EEG before drug administration revealed simi-
lar absolute power values for the first day of placebo
administration (Pl) in comparison to the first day of
active drug administration (Neu) for all electrode posi-
tions as documented in Table 1. Following drug admin-
istration no changes were documented between placebo
and verum within the first 1. 5 hours (not shown).
Three hours after administration lower spectral power
values were seen in general for the verum condition
(please compare median values in Table 2) compared to
placebo values. Only one highly statistically significant
value was recognized at the electrode position P4. At
four hours after administration again lower values were
obtained in general but only alpha waves-particularly
alpha2 frequencies at the electrode positions C3, T3, P4
and O1- showed differences to placebo values (Table 3).
Analysis of Single Brain Regions Under Mental Load
Different mental tasks produce changes of electric brain
activity within several anatomically defined brain
regions. According to earlier experience a concentration
test induces spectral frequency changes which can be
differentiated from those in the presence of memory
testing or performance of mathematical tasks. If one
compares the spectral changes during the performance
of the d2 test with the relaxed eyes open situation, brain
regions react in a different reproducible manner also in
this study. Fronto-temporal electrode positions show
increases of theta power whereas in other regions
alpha1, alpha2 and central beta1 power provide consid-
erably lower values (Figure 2). These changes in com-
parison to the eyes open situation are statistically
significant with p < 0. 05 for particular electrode posi-
tions (labelled by stars in the upper part of Figure 2).
Documentation of these changes within a brain map
containing all frequencies by additive colour mixture
(for details s. methods) reveals more increases of theta
power within left frontal cortex which leads to orange
colour dominance on this side (middle part of Figure 2).
Details of the statistical evaluation are given in the
lower part of Figure 2 corresponding to the map. High-
est significances for frequency changes during perfor-
mance of the d2 test can be documented for increased
fronto-temporal theta power and decreased alpha2 and
beta1 power in other regions. Statistically significant
decreases of alpha2 power were observed for the elec-
trode positions Cz, C3, C4, Fz, P3, P4 and O2.
A similar picture arises during the performance of
the concentration performance test (CPT), where
Table 1 Absolute spectral power values
Delta Theta Alpha 1 Alpha 2 Beta 1 Beta 2
Table of absolute values eyes open 0 h
E n Pl Neu Pl Neu Pl Neu Pl Neu Pl Neu Pl Neu
Cz 16 3. 35 4. 34 0. 60 0. 78 0. 55 0. 73 0. 43 0. 54 0. 67 0. 76 0. 90 1. 22
Fz 16 3. 42 2. 89 0. 68 0. 76 0. 67 0. 66 0. 66 0. 62 0. 54 0. 55 0. 82 0. 93
F3 16 2. 75 2. 45 0. 71 0. 59 0. 76 0. 76 0. 69 0. 54 1. 10 0. 65 2. 04 1. 60
C3 16 1. 67 2. 49 0. 46 0. 54 0. 67 0. 78 0. 59 0. 54 1. 17 1. 44 1. 75 2. 21
P3 16 1. 70 1. 71 0. 36 0. 40 0. 54 0. 42 0. 60 0. 47 0. 71 0. 80 0. 58 0. 67
Pz 16 1. 95 2. 92 0. 48 0. 55 0. 75 0. 76 0. 74 0. 70 0. 73 0. 84 0. 49 0. 60
P4 16 1. 63 1. 83 0. 35 0. 43 0. 61 0. 58 0. 63 0. 74 0. 63 0. 71 0. 46 0. 65
C4 16 1. 74 2. 23 0. 39 0. 49 0. 56 0. 74 0. 84 0. 73 1. 19 1. 38 1. 63 1. 52
F4 16 3. 22 2. 93 0. 64 0. 55 0. 67 0. 86 0. 61 0. 58 1. 07 0. 95 1. 75 2. 57
F7 16 10. 21 9. 86 1. 39 1. 42 1. 41 1. 52 1. 23 1. 40 2. 07 1. 67 3. 66 5. 09
T3 16 3. 22 5. 21 0. 77 0. 72 0. 83 1. 18 0. 97 1. 18 1. 56 2. 66 3. 25 5. 21
T5 16 3. 32 3. 13 0. 83 0. 83 1. 48 1. 68 1. 15 1. 27 1. 66 1. 89 1. 53 1. 66
O1 16 3. 41 4. 01 0. 60 0. 84 0. 86 1. 07 0. 81 0. 85 1. 22 1. 45 2. 18 1. 70
O2 16 3. 33 3. 87 0. 61 0. 75 0. 78 1. 21 1. 26 1. 17 1. 18 1. 85 1. 94 2. 47
T6 16 2. 38 3. 06 0. 67 0. 74 1. 44 1. 51 1. 26 1. 07 1. 24 1. 45 1. 33 1. 22
T4 16 4. 36 3. 84 0. 72 0. 70 0. 99 0. 81 1. 04 0. 76 1. 47 1. 31 4. 65 2. 61
F8 16 7. 09 10. 47 1. 30 1. 32 1. 45 1. 57 1. 27 1. 38 2. 03 2. 41 5. 27 5. 76
Me 16 3. 22 3. 06 0. 64 0. 72 0. 76 0. 81 0. 81 0. 74 1. 18 1. 38 1. 75 1. 66
Absolute spectral power values for each electrode position before administration of drug or placebo during relaxation under the recording condition of eyes
open. Data are given in μV
2. These data are taken as 100% reference for further evaluation. E = Electrode; Me = Median; n = number of subjects.
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Page 4 of 15Table 2 Relative spectral power values 3 h after intake of placebo or verum
Delta Theta Alpha 1 Alpha 2 Beta 1 Beta 2
Relative Change of Power (Eyes open) 3 h
E n Pl Neu Pl Neu Pl Neu Pl Neu Pl Neu Pl Neu
Cz 16 76. 26 80. 86 141. 47 101. 74 167. 62 148. 57 143. 90 129. 48 138. 02 136. 95 117. 94 112. 48
Fz 16 89. 24 101. 39 113. 30 124. 66 131. 00 124. 75 115. 87 97. 27 130. 94 108. 74 120. 41 118. 65
F3 16 108. 84 95. 86 132. 14 138. 32 131. 94 135. 07 126. 42 133. 43 144. 76 157. 32 184. 04 137. 30
C3 16 142. 33 87. 68 143. 49 108. 64 169. 91 122. 99 152. 78 125. 20 147. 19 117. 70 106. 15 122. 51
P3 16 127. 85 98. 28 145. 54 126. 43 132. 27 136. 77 121. 91 127. 87 109. 91 120. 80 94. 47 103. 24
Pz 16 130. 78 78. 11 150. 01 111. 89 168. 78 164. 56 135. 02 151. 40 113. 80 116. 45 110. 13 116. 63
P4 16 164. 93 85. 49 139. 43 109. 61 138. 61 130. 38 135. 47 121. 61 120. 43 110. 64 120. 88 99. 43
C4 16 105. 90 95. 90 132. 31 106. 03 157. 52 140. 94 147. 72 132. 68 138. 18 116. 96 111. 74 103. 87
F4 16 94. 84 102. 06 127. 60 135. 14 168. 46 120. 06 153. 12 115. 03 152. 21 124. 18 151. 04 123. 12
F7 16 90. 67 130. 51 128. 58 144. 18 130. 13 135. 33 129. 85 152. 14 142. 09 129. 21 135. 91 148. 81
T3 16 138. 06 113. 38 159. 04 148. 86 194. 55 150. 60 152. 94 151. 82 124. 67 128. 47 89. 64 129. 67
T5 16 133. 63 112. 75 157. 72 123. 87 174. 70 149. 38 133. 22 118. 85 111. 39 123. 76 102. 13 100. 98
O1 16 115. 66 99. 28 131. 58 134. 39 144. 72 109. 64 132. 79 106. 45 144. 80 119. 48 128. 06 119. 81
O2 16 125. 27 87. 80 146. 25 112. 16 151. 53 104. 05 136. 12 118. 63 138. 64 112. 42 136. 18 105. 26
T6 16 147. 70 130. 73 154. 25 134. 24 156. 65 156. 08 145. 83 131. 83 119. 85 117. 06 94. 77 93. 16
T4 16 126. 46 134. 52 134. 62 136. 48 148. 01 160. 42 140. 19 133. 87 112. 93 111. 05 93. 34 109. 90
F8 16 138. 90 139. 66 140. 93 149. 02 129. 44 141. 96 130. 45 114. 66 125. 83 117. 55 126. 19 102. 40
Me 16 126. 46 99. 28 140. 93 126. 43 151. 53 136. 77 135. 47 127. 87 130. 94 117. 70 117. 94 112. 48
Relative power values (% of pre-drug) for each electrode position 3 h after administration of drug or placebo during relaxation under the recording condition of
eyes open 4 h after intake of placebo or verum. Statistically significant different values in comparison to placebo (p = 0. 021) are printed fat. E = Electrode; Me =
Median; n = number of subjects.
Table 3 Relative spectral power values 4 h after intake of placebo or verum
Delta Theta Alpha 1 Alpha 2 Beta 1 Beta 2
Relative Change of Power (Eyes open) 4 h
E n Pl Neu Pl Neu Pl Neu Pl Neu Pl Neu Pl Neu
Cz 16 92. 93 85. 06 120. 76 115. 00 160. 49 134. 92 178. 70 129. 99 134. 43 136. 66 129. 63 119. 80
Fz 16 110. 12 106. 59 126. 85 126. 92 153. 09 126. 83 149. 41 108. 82 141. 30 110. 69 109. 46 114. 19
F3 16 130. 77 121. 17 131. 11 133. 99 143. 29 131. 57 146. 84 126. 35 152. 52 129. 60 139. 15 136. 29
C3 16 143. 39 103. 03 161. 99 106. 40 184. 32 125. 74 199. 06 122. 00 163. 24 119. 82 131. 87 91. 23
P3 16 125. 22 101. 65 139. 11 129. 07 127. 10 129. 55 135. 28 129. 60 112. 85 123. 79 107. 19 110. 95
Pz 16 122. 58 102. 78 118. 77 117. 04 138. 91 122. 57 140. 81 134. 61 122. 99 122. 09 116. 98 120. 23
P4 16 169. 23 90. 46 161. 94 123. 27 146. 17 126. 59 149. 79 123. 37 132. 53 112. 93 124. 39 106. 21
C4 16 108. 49 91. 85 139. 05 111. 22 154. 92 144. 81 179. 28 125. 38 132. 69 129. 46 137. 85 113. 68
F4 16 117. 70 138. 61 129. 74 130. 22 158. 47 118. 51 154. 69 109. 41 162. 97 130. 81 134. 72 114. 71
F7 16 122. 49 180. 62 154. 49 152. 29 146. 71 147. 22 131. 11 147. 22 137. 28 132. 59 141. 24 145. 14
T3 16 155. 39 151. 76 218. 06 137. 20 210. 65 141. 20 212. 31 138. 22 143. 21 127. 92 128. 86 91. 49
T5 16 132. 15 144. 40 153. 07 134. 47 153. 93 153. 34 147. 75 136. 95 123. 87 129. 40 109. 77 115. 14
O1 16 136. 22 108. 16 137. 12 124. 71 166. 38 118. 52 171. 29 115. 74 170. 13 122. 99 140. 16 95. 78
O2 16 118. 31 101. 77 154. 50 121. 48 162. 00 114. 22 152. 19 118. 28 143. 77 116. 68 131. 18 107. 77
T6 16 175. 11 147. 15 156. 15 140. 95 154. 38 145. 39 138. 18 130. 82 119. 30 116. 71 106. 77 109. 75
T4 16 156. 82 167. 62 155. 88 142. 24 173. 66 157. 10 142. 40 148. 35 140. 33 134. 77 137. 56 111. 50
F8 16 167. 63 130. 59 138. 15 144. 36 141. 56 145. 84 137. 09 115. 38 139. 92 117. 06 132. 92 117. 37
Me 16 130. 77 108. 16 139. 11 129. 07 154. 38 131. 57 149. 41 126. 35 139. 92 123. 79 131. 18 113. 68
Relative power values (% of pre-drug) for each electrode position 4 h after administration of drug or placebo during relaxation under the recording condition of
eyes open 4 h after intake of placebo or verum. Statistically significant different values in comparison to placebo (p = 0. 021) are printed fat. E = Electrode; Me =
Median; n = number of subjects.
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Page 5 of 15mathematical calculations have to be done. Large
increases of left and middle frontal theta power are
accompanied by massive decreases mainly in centro-par-
ietal alpha2 spectral power involving also some areas
with decrease in beta1 power. These changes in
comparison to the relaxed eyes open status are also sta-
tistically highly significant (labelled by stars in Figure 3).
Increases of left frontal theta power are also recognized
in the map (middle part of Figure 3). Statistically signifi-
cant decreases of alpha2 power in other regions were
Figure 2 Physiological changes of spectral frequency content during d2 test. Depiction of frequency changes at all electrode positions
during the performance of the d2 test in comparison to the relaxed eyes-open state at the first visit (day A). Colour vision map with
interpolated data is constructed as described under methods. Statistically significant changes between these two states are marked by an
asterisk and depicted with respect to position in the map. Left side of figure corresponds to frontal brain region.
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Page 6 of 15observed for the electrode positions Cz, C3, Fz, P3, Pz,
P4 and O1.
During the performance of the memory test, where a
row of 8 combined letters and numbers have to be
memorized within 4 seconds, also left and right frontal
delta and theta power increase in a highly significant
manner (labelled by stars in the upper part of Figure 4)
which also leads to dominant red-yellow colour
increases in the brain map (middle part of Figure 4).
Details of the statistically significant differences in
Figure 3 Physiological changes of spectral frequency content during CPT. Depiction of frequency changes at all electrode positions during
the performance of the d2 test in comparison to the relaxed eyes-open state at the first visit (day A) before drug administration. Colour vision
map with interpolated data is constructed as described under methods. Statistically significant changes between these two states are marked by
an asterisk star and depicted with respect to position in the map. Left side of figure corresponds to frontal brain region.
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Page 7 of 15Figure 4 Physiological changes of spectral frequency content during memory test. Depiction of frequency changes at all electrode
positions during the performance of the d2 test in comparison to the relaxed eyes-open state at the first visit (day A). Colour vision map with
interpolated data is constructed as described under methods. Statistically significant changes between these two states are marked by an
asterisk and depicted with respect to position in the map. Left side of figure corresponds to frontal brain region.
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Page 8 of 15comparison to the relaxed status are documented in the
lower part of Figure 4. Statistically significant decreases
of alpha2 power were observed for the electrode posi-
tions Cz, Fz, P3, P4 and O1.
Thus, all three mental loads lead to somewhat differ-
ent changes of frequency patterns in comparison to the
relaxed state but have in common a fronto-temporal
increase in delta and/or theta power with significant
decreases of alpha and beta1 power in other brain
regions.
Analysis of Drug Effects in the Presence of Various Mental
Loads
No significant differences between verum and placebo
were seen with regard to fronto-temporal delta/theta
power increases. In order to better interpret the effects
of the drug on electric spectral power, medium power
of those electrode positions involved in the statistically
significant (at least by p < 0. 05) decrease of alpha2
power during mental work were unified to give one
parameter set. They represent a brain region heavily
involved in the process of a particular mental task
performance.
Recording under the three different mental perfor-
mance conditions succeeded in uncovering drug-
induced changes within the alpha and beta1 spectral fre-
quencies during the 3
rd and 4
th hour after drug adminis-
tration. Results for the d2 test are given in Figure 5.
Under this recording condition statistically significant
lower power values of alpha1, alpha2 and beta1 power
were observed 3 and/or 4 hours after administration of
verum in comparison to placebo. Regarding the data
during performance of the CPT again statistically signifi-
cantly lower values were obtained during the 4
th hour
after administration for theta, alpha1 and beta1 spectral
power (Figure 6). During the 3
rd and 4
th hour perfor-
mance of the memory test led to significantly dimin-
ished values of alpha1 and alpha2 spectral power in
comparison to placebo, too (Figure 7).
Thus, during all mental tasks alpha and beta1 power
was statistically significantly lower in the presence of
verum in comparison to placebo. Analysis of the psy-
chometric results revealed either no difference (Table 4)
or a trend of better performance for the CPT at 3 and 4
hours after administration (Table 5), which, however,
was not statistically significant, or no difference during
the memory test (Table 6).
Discussion
Since it is quite difficult to evaluate the data from 17
electrode positions in the presence of 6 frequency
ranges (a total of 102 parameters) the mathematical tool
of discriminant analysis was used to describe the action
of the active drug in comparison to placebo for the
recording condition eyes open. This method allows
time-dependent evaluation of all changes with respect to
the pre-drug condition. As can be seen in Figure 8 all
placebo values (labelled PL05 to PL4)-representing cir-
cadian rhythm dependent changes-group together with
the two first recordings from active drug at 0. 5 to 1. 5
hours after administration (labelled Neu05 and Neu15).
Depiction of the result of the effect of verum at 3 and 4
hours after administration in comparison to the effect of
other synthetic reference drugs or plant-derived pre-
parations tested earlier revealed clear effects for the
active drug (labelled Neu3 and Neu4 in Figure 8). Clo-
sest neighbours in space (representing the result of the
first to third discriminant function) but with a different
colour due to the result of the fourth to sixth discrimi-
nant function are Nutrifin-relax and L-Theanine.
Another neighbour not too far away with the same col-
our is fluoxetine.
This kind of analysis of the experimental series
revealed that the preparation NEURAPAS
® balance
modulated electric brain activity already after a single
acute administration in a statistically significant manner
in comparison to placebo. Three and four hours after
the administration of verum, basic activity has changed
t oac o n s i d e r a b l ed e g r e ei nc o m p a r i s o nt op l a c e b o
according to this analysis. The pattern of changes
approached that seen after reference drugs or prepara-
tions like Nutrifin-relax, a plant-derived preparation
marketed to cope with stress [9]. Furthermore, fluoxe-
tine, a chemical reference drug with clinically proven
anti-depressive effects [17] is projected within the docu-
mentation of the result of discriminant analysis more
close than to a preparation of St. John’s wort tested ear-
lier under identical conditions (results not shown).
Comparison with a previous study shows that the pro-
jection of Neurapas
® balance is close to that of ginkgo/
ginseng. This vicinity of the projection of gingko/gin-
seng effects on electric activity of the brain suggests
beneficial effects [18], since clinically significant
improvement in memory loss, concentration, fatigue,
anxiety and depressed mood associated with ginkgo/gin-
seng has been reported in the literature [19]. This sug-
gests that NEURAPAS
® balance might unify anti-
depressive and relaxing features as claimed by the
design of the combination according to known effects of
single extracts from St. John’sw o r t ,v a l e r i a n ,a n dp a s -
sion flower (see reference under “background “).
Spectral power of frequencies, which predominantly
were attenuated during performance of mental work in
more centro-parietal areas of the brain, remain low 3
and 4 hours after administration of the active prepara-
tion in comparison to placebo (which led to an increase
of spectral power rather than the decrease observed in
the pre-drug condition!). This suggests that mental
Dimpfel et al. BMC Psychiatry 2011, 11:123
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Page 9 of 15processing ability is relatively preserved 3-4 hours after
administration of NEURAPAS
® balance compared to
the placebo condition, where increases of alpha and beta
spectral power were observed presumably due to circa-
dian rhythms and/or fatigue. Even if there was no differ-
ence in psychometric results, some higher values were
noted with respect to the concentration performance
test (CPT), where highest performance was recorded
during the 3
rd and 4
th hour after administration, perhaps
related to the relative constancy of EEG spectra.
For St. John’s wort maximum effects after single dose
administration have been observed between 4 and 6
hours after administration [20]. This is in line with the
current results, where no effects could be recognized
Figure 5 Drug-induced changes of spectral frequency content during d2 test. Time dependence of spectral frequency changes during
performance of the d2 test in the presence of placebo or verum. Choice of electrode positions in concordance with statistically significant
changes observed during this test condition (s. Figure 3). * corresponds to p < 0. 12; ** corresponds to p < 0. 076; *** corresponds to p < 0. 02.
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Page 10 of 15before the 3rd hour after administration. Better cogni-
tive functioning in the presence of one of the ingredi-
ents (St. John’s wort) has been claimed on the basis of
EEG recording by [21]. But, due to the combination of
three plant-derived extracts the effects cannot be attrib-
uted to one of them. However, it is important to note,
that at least no interference with cognitive performance
could be seen as reported repeatedly during the use of
other synthetic preparations like benzodiazepines as
anti-anxiety drugs or serotonin-reuptake inhibitors for
treatment of depression [1]. With respect to the ratio-
nale of combining the three extracts a more potent neu-
roactivity of the triple combination compared to
Hypericum alone and the additive effects of Passiflora
and Valeriana suggested a synergy between constituents
of these herbal extracts as derived from in vitro
Figure 6 Drug-induced changes of spectral frequency content during CPT.T i m ed e p e n d e n c eo fs p e c t r a lf r e q u e n c yc h a n g e sd u r i n g
performance of the CPT in the presence of placebo or verum. Choice of electrode positions in concordance with statistically significant changes
observed during this test condition (s. Figure 4). * corresponds to p < 0. 12; ** corresponds to p < 0. 076; *** corresponds to p < 0. 02.
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Page 11 of 15experiments with multielectrode neurochips [22]. This
study indicated that the ingredients of NEURAPAS
®
balance act on GABA and serotonin receptors. Involve-
ment of the GABAergic transmission has also been
claimed for one of the constituents of the triple combi-
nation (Passiflora incarnate) by in vivo trials by [23] as
well as in vitro experiments [24].
EEG frequencies reflect the activity of particular neu-
rotransmitter activities as discovered earlier in preclini-
cal studies using recording from depth electrodes in
freely moving rats. From these earlier preclinical experi-
ments is became clear that alpha1 waves seem to be
related to serotonergic transmission [25] and that
alpha2 waves seem to be related to the activity of
Figure 7 Drug-induced changes of spectral frequency content during memory test.T i m ed e p e n d e n c eo fs p e c t r a lf r e q u e n c yc h a n g e s
during performance of the memory test in the presence of placebo or verum. Choice of electrode positions in concordance with statistically
significant changes observed during this test condition (s. Figure 5). * corresponds to p < 0. 12; ** corresponds to p < 0. 076; *** corresponds to
p < 0. 02.
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Page 12 of 15dopamine [26]. Based on these preclinical results one
might interpret the data obtained with respect to
NEURAPAS
® balance in a sense that ingredients con-
tained within this extract combination activate seroto-
nergic and dopaminergic transmission. These two
transmitters are well known to be involved in depression
and anxiety. Synthetic drugs acting at receptors of these
two neurotransmitters are prescribed first line to treat
these psychiatric conditions, especially serotonin-reup-
take inhibitors for the treatment of depression. Some
decreased values of alpha1 and alpha2 waves during the
recording condition “eyes open” are therefore in line
with the view that NEURAPAS
® balance activates these
transmitter systems and initiates its action already after
the first intake.
Finally, the question of combining different extracts
must be tackled. According to literature changes of the
EEG in the presence of for example valerian roots extract
could not be shown, even at dosages as high as 300 or
600 mg [27]. Also with respect to St. John’sw o r td o s a g e s
as high as 900 mg had to be given in order to see
changes of electrical activity [20]. Positive results with an
extract from passion-flower were obtained with a dose of
425 mg native extract (to be published). Thus, the rela-
tively low amounts of the single extracts combined within




0 h Mean 12,32 12,14
SD 4,02 3,06
SEM 1,07 0,80
0,5 h Mean 13,67 13,09
SD 3,82 3,27
SEM 1,02 0,84
1,5 h Mean 13,62 13,71
SD 4,22 3,89
SEM 1,12 0,91
3 h Mean 13,35 13,19
SD 3,95 3,27
SEM 1,05 0,84
4 h Mean 13,59 13,53
SD 3,77 3,13
SEM 1,01 0,82
Listing of psychometric results for three different mental tests:




0 h Mean 6,57 5,59
SD 6,17 5,95
SEM 1,61 1,59
0,5 h Mean 5,32 5,91
SD 4,57 4,94
SEM 1,20 1,25
1,5 h Mean 6,55 5,85
SD 5,98 4,93
SEM 1,58 1,29
3 h Mean 5,93 6,97
SD 5,33 5,83
SEM 1,41 1,52
4 h Mean 6,87 7,86
SD 7,30 5,76
SEM 1,93 1,52
Listing of psychometric results for three different mental tests:




0 h Mean 10,77 11,37
SD 3,98 3,64
SEM 1,06 0,92
0,5 h Mean 10,95 11,38
SD 4,10 3,60
SEM 1,10 0,96
1,5 h Mean 10,68 11,29
SD 4,46 3,13
SEM 1,19 0,80
3 h Mean 11,11 12,12
SD 4,38 3,75
SEM 1,07 1,00
4 h Mean 11,51 11,95
SD 3,74 3,65
SEM 0,99 0,92
Listing of psychometric results for three different mental tests:
Figure 8 Discriminant Analysis of EEG source density data.
Depiction of the result of linear discriminant analysis of EEG source
density data for all four recording periods after administration of
verum and placebo. Result from the first three discriminant
functions is displayed by means of space coordinates x, y and z.
Values of the 4
th to 6
th linear discriminant functions respectively
determine the amount of red, green, and blue in additive colour
mixture analogous to the RGB mode of TV.
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Page 13 of 15NEURAPAS
® balance speak in favour of not only addi-
tive but potentiating effects of single ingredients from St.
John’s wort herb, valerian root, and passion flower herb
in order to produce the electric profile of effects on the
human brain as described above.
Conclusions
Administration of NEURAPAS
® balance resulted in a
prevention of circadian EEG changes which normally
consist in increases of spectral power in all six frequency
ranges. Under the condition of mental work this
attenuation became statistically significant for alpha and
partially beta waves at 3 and 4 hours after intake. No
cognitive impairment could be shown during the
recording period according to analysis of psychometric
testing. Linear discriminant analysis showed that the
effects of NEURAPAS
® balance are more comparable to
the effects of Fluoxetine (a synthetic antidepressant
drug) than to those in the presence of St. John’sw o r t
extract without producing side effects.
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